• Youssef Alqahtani, Mohammed Oshi, Naglaa M Kamal, Mohammed Aljabri, Salma Abosabie, Waleed Elhaj, and Sara A Abosabie.
• Department of Child Health, College of Medicine, King Khalid University, Abha, Kingdom of Saudi Arabia.
• Medicine (Baltimore). 2023 Feb 22; 102 (8): e32986e32986.

BackgroundMyelin oligodendrocyte glycoprotein antibody (MOGA) associated diseases are inflammatory immune-mediated demyelinating disorders with relapse potential involving the central nervous system. Multiple unusual clinical manifestations of those disorders were reported, making treatment decisions difficult.Case PresentationA healthy 12-year-old obese boy presented with headache and bilateral asymmetric papilledema. The patient had a negative medical history. His neurological and general examinations were unremarkable, his initial magnetic resonance imaging showed elevated intracranial pressure (ICP) only. A lumbar puncture revealed increased opening pressure and pleocytosis. The MOGA titer was 1:320. He needed acetazolamide and steroid therapy. After 2 months of medication, weight loss, exercise, the patient symptoms significantly improved, papilledema resolved, and visual function improved.ConclusionMOGA-associated disorders have a variety of clinical features, so a high index of suspicion is required for their diagnosis. Papilledema and an elevated ICP are 2 of the chameleons of MOGA-associated disorders. MOGA test may be useful in patients with elevated ICP and inflammatory cerebrospinal fluid profiles. An investigation of the possible association between those disorders and high ICP is warranted.Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.

20 keywords...

hide…